^
    Back
    Association details:
    Biomarker:Chr del(11q)
    Cancer:Chronic Lymphocytic Leukemia
    Regimen: (fludarabine IV + cyclophosphamide + Rituxan (rituximab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Br J Haematol
    Title:

    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group

    Published date:
    02/22/2021
    Excerpt:
    Between March 2009 and July 2012, we enrolled 107 patients considered ineligible for full-dose FCR...The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months), especially in absence of del 11q or 17p (median 74 months). Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology.
    DOI:
    10.1111/bjh.17373